CollPlant Holdings

US: CLGN

Market CapNIS75m

Last Close NIS0.43

CollPlant is an Israel-based regenerative medicine company. It is focused on developing and commercializing tissue repair products with its plant-based technology, rhCollagen. It has two products on the market, VergenixSTR and Vergenix FG, and has received several orders for its 3D bioprinting product bioInk.

More CollPlant Holdings content >

Investment summary

Edison Investment Research is terminating coverage on CollPlant Holdings (CLGN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec
Revenue (NISm)
EBITDA (NISm)
PBT (NISm)
EPS (NIS)
P/E (x)
P/CF (x)
2016A 0.3 (27.0) (27.9) (27.72) N/A N/A
2017A 1.7 (19.7) (20.9) (15.68) N/A N/A
2018E 21.1 (11.8) (12.7) (6.10) N/A N/A
2019E 7.3 (18.7) (20.1) (8.57) N/A N/A
Content on CollPlant Holdings
CollPlant Holdings – Termination of coverage
Healthcare | Termination | 4 January 2019
View more
Share price graph
Balance sheet
Forecast net cash (NISm) 18.7
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 12.63 (9.32) (19.85)
Relative* 17.541 (10.614) (25.781)
52-week high/low NIS0.6/NIS0.4
*% relative to local index
Key management
Yehiel Tal CEO
Eran Rotem CFO